Cargando…
Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial
BACKGROUND AND OBJECTIVE: Forced vital capacity (FVC) less than 50% of predicted is one of the main parameters used for Non-Invasive Ventilation (NIV) initiation in Amyotrophic Lateral Sclerosis (ALS). Recent studies suggest that higher values of FVC could be considered as a threshold. The aim of th...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357175/ https://www.ncbi.nlm.nih.gov/pubmed/37212068 http://dx.doi.org/10.3233/JND-221658 |
_version_ | 1785075438617362432 |
---|---|
author | Sarasate, Mikel González, Nuria Córdoba-Izquierdo, Ana Prats, Enric Gonzalez-Moro, Jose Miguel Rodriguez Martí, Sergi Lujan, Manel Calle, Myriam Antón, Antonio Povedano, Mónica Farrero, Eva |
author_facet | Sarasate, Mikel González, Nuria Córdoba-Izquierdo, Ana Prats, Enric Gonzalez-Moro, Jose Miguel Rodriguez Martí, Sergi Lujan, Manel Calle, Myriam Antón, Antonio Povedano, Mónica Farrero, Eva |
author_sort | Sarasate, Mikel |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Forced vital capacity (FVC) less than 50% of predicted is one of the main parameters used for Non-Invasive Ventilation (NIV) initiation in Amyotrophic Lateral Sclerosis (ALS). Recent studies suggest that higher values of FVC could be considered as a threshold. The aim of this study is to evaluate whether early use of NIV improves the prognosis of ALS patients compared with standard initiation. METHODS: This is a randomized, parallel, multicenter, open-label, controlled clinical trial, with recruitment at the ALS outpatient multidisciplinary units of six Spanish hospitals. Patients were included when their FVC reached the 75% threshold and were randomized by computer, stratifying by center in an allocation ratio of 1:1 to Early NIV (FVC below 75%) or Standard NIV (FVC below 50%) initiation. The primary outcome was time to death or tracheostomy. Trial registration number ClinicalTrials.gov: NCT01641965. RESULTS: Between May 2012 and June 2014, 42 patients were randomized to two groups, 20 to Early NIV and 22 to Standard NIV initiation. We found differences in survival in favor of the intervention group: an incidence of mortality (2.68 [1.87–5.50] vs. 3.33 [1.34–4.80] person-months) and a median survival (25.2 vs. 19.4 months), although without reaching statistical significance (p = 0.267). CONCLUSIONS: This trial did not reach the primary endpoint of survival; nevertheless, it is the first Randomized Controlled Trial (RCT) to demonstrate the benefits of early NIV in slowing the decline of respiratory muscle strength and reducing adverse events. Although not all the results reached statistical significance, all the analyzed data favor early NIV. In addition, this study demonstrates good tolerance and compliance with early NIV without quality of sleep impairment. These data reinforce the early respiratory evaluation of ALS patients and NIV initiation with an FVC of around 75%. |
format | Online Article Text |
id | pubmed-10357175 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-103571752023-07-21 Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial Sarasate, Mikel González, Nuria Córdoba-Izquierdo, Ana Prats, Enric Gonzalez-Moro, Jose Miguel Rodriguez Martí, Sergi Lujan, Manel Calle, Myriam Antón, Antonio Povedano, Mónica Farrero, Eva J Neuromuscul Dis Research Report BACKGROUND AND OBJECTIVE: Forced vital capacity (FVC) less than 50% of predicted is one of the main parameters used for Non-Invasive Ventilation (NIV) initiation in Amyotrophic Lateral Sclerosis (ALS). Recent studies suggest that higher values of FVC could be considered as a threshold. The aim of this study is to evaluate whether early use of NIV improves the prognosis of ALS patients compared with standard initiation. METHODS: This is a randomized, parallel, multicenter, open-label, controlled clinical trial, with recruitment at the ALS outpatient multidisciplinary units of six Spanish hospitals. Patients were included when their FVC reached the 75% threshold and were randomized by computer, stratifying by center in an allocation ratio of 1:1 to Early NIV (FVC below 75%) or Standard NIV (FVC below 50%) initiation. The primary outcome was time to death or tracheostomy. Trial registration number ClinicalTrials.gov: NCT01641965. RESULTS: Between May 2012 and June 2014, 42 patients were randomized to two groups, 20 to Early NIV and 22 to Standard NIV initiation. We found differences in survival in favor of the intervention group: an incidence of mortality (2.68 [1.87–5.50] vs. 3.33 [1.34–4.80] person-months) and a median survival (25.2 vs. 19.4 months), although without reaching statistical significance (p = 0.267). CONCLUSIONS: This trial did not reach the primary endpoint of survival; nevertheless, it is the first Randomized Controlled Trial (RCT) to demonstrate the benefits of early NIV in slowing the decline of respiratory muscle strength and reducing adverse events. Although not all the results reached statistical significance, all the analyzed data favor early NIV. In addition, this study demonstrates good tolerance and compliance with early NIV without quality of sleep impairment. These data reinforce the early respiratory evaluation of ALS patients and NIV initiation with an FVC of around 75%. IOS Press 2023-07-04 /pmc/articles/PMC10357175/ /pubmed/37212068 http://dx.doi.org/10.3233/JND-221658 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Report Sarasate, Mikel González, Nuria Córdoba-Izquierdo, Ana Prats, Enric Gonzalez-Moro, Jose Miguel Rodriguez Martí, Sergi Lujan, Manel Calle, Myriam Antón, Antonio Povedano, Mónica Farrero, Eva Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial |
title | Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial |
title_full | Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial |
title_fullStr | Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial |
title_full_unstemmed | Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial |
title_short | Impact of Early Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis: A multicenter Randomized Controlled Trial |
title_sort | impact of early non-invasive ventilation in amyotrophic lateral sclerosis: a multicenter randomized controlled trial |
topic | Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357175/ https://www.ncbi.nlm.nih.gov/pubmed/37212068 http://dx.doi.org/10.3233/JND-221658 |
work_keys_str_mv | AT sarasatemikel impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT gonzaleznuria impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT cordobaizquierdoana impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT pratsenric impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT gonzalezmorojosemiguelrodriguez impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT martisergi impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT lujanmanel impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT callemyriam impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT antonantonio impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT povedanomonica impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial AT farreroeva impactofearlynoninvasiveventilationinamyotrophiclateralsclerosisamulticenterrandomizedcontrolledtrial |